Best practices in the treatment of early cystic fibrosis lung disease

Marijke Proesmans, Marijke Proesmans

Abstract

For many years, management of cystic fibrosis (CF) lung disease was focused on symptomatic treatment of chronic lung infection, which is characterized by cough and sputum production, leading to progressive lung damage. With increasing survival and better knowledge of the pathogenesis of CF lung disease, it has become clear that treatment has to start very early because lung damage occurs in young patients, often before obvious symptoms appear. The arrival of new cystic fibrosis transmembrane conductance-regulator (CFTR)-correcting therapies will bring more opportunities to prevent the disease, apart from only treating chronic lung infection. In this review, a summary of the current knowledge of early CF lung disease is provided, based on animal model studies, as well as on data obtained from well structured follow-up programs after newborn screening (NBS). The most important clinical guidelines for treating young CF patients are also summarized.

Keywords: animal models; cystic fibrosis; early therapy; lung disease; newborn screening.

Conflict of interest statement

Conflict of interest statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Pathogenesis of early CF lung disease. CFTR, cystic fibrosis transmembrane conductance regulator.

References

    1. Ahmed M., Mukherjee S. (2016). Treatment for chronic methicillin-sensitive staphylococcus aureus pulmonary infection in people with cystic fibrosis. Cochrane Database Syst Rev 3: CD011581.
    1. Al-Saleh S., Dell S., Grasemann H., Yau Y., Waters V., Martin S., et al. (2010). Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr 157: 1006–1011.
    1. Amin R., Subbarao P., Jabar A., Balkovec S., Jensen R., Kerrigan S., et al. (2010). Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 65: 379–383.
    1. Amin R., Subbarao P., Lou W., Jabar A., Balkovec S., Jensen R., et al. (2011). The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 37: 806–812.
    1. Aurora P., Stanojevic S., Wade A., Oliver C., Kozlowska W., Lum S., et al. (2011). Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis. Am J Respir Crit Care Med 183: 752–758.
    1. Balfour-Lynn I., Welch K. (2014). Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev CD001915.
    1. Brennan L.C., Thia L.P. (2013). Evolution of lung function during the first two years of life in infants with cystic fibrosis diagnosed by newborn screening. Thorax 68(Suppl 3): A1–A220.
    1. Bush A., Sly P. (2015). Evolution of cystic fibrosis lung function in the early years. Curr Opin Pulm Med 21: 602–608.
    1. Castellani C., Massie J., Sontag M., Southern K. (2016). Newborn screening for cystic fibrosis. Lancet Respir Med 4: 653–661.
    1. Cystic Fibrosis Foundation, Borowitz D., Parad R., Sharp J., Sabadosa K., Robinson K., et al. (2009). Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 155: S106–S116.
    1. Davies J., Cunningham S., Harris W., Lapey A., Regelmann W., Sawicki G., et al. (2016). Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med 4: 107–115.
    1. Davies J., Sheridan H., Bell N., Cunningham S., Davis S., Elborn J., et al. (2013). Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med 1: 630–638.
    1. De Boeck K., Alifier M., Vandeputte S. (2000). Sputum induction in young cystic fibrosis patients. Eur Respir J 16: 91–94.
    1. De Jong P., Nakano Y., Lequin M., Mayo J., Woods R., Pare P., et al. (2004). Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 23: 93–97.
    1. Doring G., Flume P., Heijerman H., Elborn J.: Consensus Study Group. (2012). Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 11: 461–79.
    1. Elborn J. (2016). Cystic fibrosis. Lancet pii: S0140-6736(16)00576-6.
    1. Fischer A., Singh S., Adam R., Stoltz D., Baranano C., Kao S., et al. (2014). Tracheomalacia is associated with lower FEV1 and Pseudomonas acquisition in children with CF. Pediatr Pulmonol 49: 960–970.
    1. Gustafsson P., de Jong P., Tiddens H., Lindblad A. (2008). Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 63: 129–134.
    1. Hoegger M., Fischer A., McMenimen J., Ostedgaard L., Tucker A., Awadalla M., et al. (2014). Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 345: 818–822.
    1. Hoen A., Li J., Moulton L., O’Toole G., Housman M., Koestler D., et al. (2015). Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis. J Pediatr 167: 138–147.
    1. Jain K., Wainwright C., Smyth A. (2013). Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. Cochrane Database Syst Rev: CD009530.
    1. Kuo W., Ciet P., Tiddens H., Zhang W., Guillerman R., van Straten M. (2014). Monitoring cystic fibrosis lung disease by computed tomography. Radiation risk in perspective. Am J Respir Crit Care Med 189: 1328–1336.
    1. Lahiri T., Hempstead S., Brady C., Cannon C., Clark K., Condren M., et al. (2016). Clinical practice guidelines from the cystic fibrosis foundation for preschoolers with cystic fibrosis. Pediatrics 137(4): 1–28.
    1. Mazur N., Martinon-Torres F., Baraldi E., Fauroux B., Greenough A., Heikkinen T., et al. (2015a). Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med 3: 888–900.
    1. Mazur N., van Delden J., Bont L. (2015b). Respiratory syncytial virus trials and beyond. Lancet Infect Dis 15: 1363–1365.
    1. Meyerholz D. (2016). Lessons learned from the cystic fibrosis pig. Theriogenology 86: 427–432.
    1. Mika M., Korten I., Qi W., Regamey N., Frey U., Casaulta C., et al. (2016). The nasal microbiota in infants with cystic fibrosis in the first year of life: a prospective cohort study. Lancet Respir Med 4: 627–635.
    1. Mogayzel P., Jr., Naureckas E., Robinson K., Brady C., Guill M., Lahiri T., et al. (2014). Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc 11: 1640–1650.
    1. Mussaffi H., Fireman E., Mei-Zahav M., Prais D., Blau H. (2008). Induced sputum in the very young: a new key to infection and inflammation. Chest 133: 176–182.
    1. Nguyen T., Thia L., Hoo A., Bush A., Aurora P., Wade A., et al. (2014). Evolution of lung function during the first year of life in newborn screened cystic fibrosis infants. Thorax 69: 910–917.
    1. Quan J., Tiddens H., Sy J., McKenzie S., Montgomery M., Robinson P., et al. (2001). A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 139: 813–20.
    1. Ramsey B., Davies J., McElvaney N., Tullis E., Bell S., Drevinek P., et al. (2011). A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365: 1663–1672.
    1. Ramsey K., Rosenow T., Turkovic L., Skoric B., Banton G., Adams A., et al. (2016). Lung Clearance Index and Structural Lung Disease on Computed Tomography in Early Cystic Fibrosis. Am J Respir Crit Care Med 193: 60–67.
    1. Riordan J., Rommens J., Kerem B., Alon N., Rozmahel R., Grzelczak Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066–1073.
    1. Rogers C., Stoltz D., Meyerholz D., Ostedgaard L., Rokhlina T., Taft P., et al. (2008). Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 321: 1837–1841.
    1. Rosenfeld M., Ratjen F., Brumback L., Daniel S., Rowbotham R., McNamara S., et al. (2012). Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 307: 2269–2277.
    1. Sawicki G., McKone E., Pasta D., Millar S., Wagener J., Johnson C., et al. (2015). Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med 192: 836–842.
    1. Sims E., Clark A., McCormick J., Mehta G., Connett G., Mehta A., et al. (2007). Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics 119: 19–28.
    1. Sly P., Brennan S., Gangell C., de Klerk N., Murray C., Mott L., et al. (2009). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 180: 146–152.
    1. Smyth A., Bell S., Bojcin S., Bryon M., Duff A., Flume P., et al. (2014). European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros 13: S23–S42.
    1. Sonneveld N., Stanojevic S., Amin R., Aurora P., Davies J., Elborn J., et al. (2015). Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations. Eur Respir J 46: 1055–1064.
    1. Southern K., Barker P., Solis-Moya A., Patel L. (2012). Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 11: CD002203.
    1. Stick S., Brennan S., Murray C., Douglas T., von Ungern-Sternberg B., Garratt L., et al. (2009). Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 155: 623–628 e1.
    1. Stoltz D., Meyerholz D., Pezzulo A., Ramachandran S., Rogan M., Davis G., et al. (2010). Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2: 29ra31.
    1. Subbarao P., Stanojevic S., Brown M., Jensen R., Rosenfeld M., Davis S., et al. (2013). Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. Am J Respir Crit Care Med 188: 456–460.
    1. Wainwright C., Vidmar S., Armstrong D., Byrnes C., Carlin J., Cheney J., et al. (2011). Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 306: 163–171.
    1. Wielputz M., Mall M. (2015). Imaging modalities in cystic fibrosis: emerging role of MRI. Curr Opin Pulm Med 21: 609–616.
    1. Yammine S., Bigler A., Casaulta C., Singer F., Latzin P. (2014). Reasons for heterogeneous change in LCI in children with cystic fibrosis after antibiotic treatment. Thorax 69: 183.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren